BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1994 related articles for article (PubMed ID: 27627752)

  • 21. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Miere A; Querques G; Semoun O; Amoroso F; Zambrowski O; Chapron T; Capuano V; Souied EH
    Retina; 2017 Oct; 37(10):1873-1879. PubMed ID: 28079756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodal imaging of early stage 1 type 3 neovascularization with simultaneous eye-tracked spectral-domain optical coherence tomography and high-speed real-time angiography.
    Querques G; Souied EH; Freund KB
    Retina; 2013 Oct; 33(9):1881-7. PubMed ID: 23644560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multilayered pigment epithelial detachment in neovascular age-related macular degeneration.
    Rahimy E; Freund KB; Larsen M; Spaide RF; Costa RA; Hoang Q; Christakopoulos C; Munch IC; Sarraf D
    Retina; 2014 Jul; 34(7):1289-95. PubMed ID: 24675391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
    Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
    Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration.
    Giansanti F; Bacherini D; Giacomelli G; Virgili G; Finocchio L; Fiore T; Vannozzi L; Menchini U
    Eur J Ophthalmol; 2014; 24(3):402-8. PubMed ID: 24242217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPATIAL PATTERN OF RETINAL PIGMENT EPITHELIUM TEAR DEVELOPMENT AND PROGRESSION AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Fukui T; Ishikawa K; Shiose S; Kano K; Mori K; Notomi S; Sonoda KH
    Retin Cases Brief Rep; 2024 May; 18(3):371-377. PubMed ID: 36730109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Invernizzi A; Nguyen V; Arnold J; Young S; Barthelmes D; Gillies MC
    Ophthalmology; 2018 Feb; 125(2):237-244. PubMed ID: 28993010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Cho HJ; Kim HS; Yoo SG; Han JI; Lew YJ; Cho SW; Lee TG; Kim JW
    Retina; 2016 Oct; 36(10):1851-9. PubMed ID: 27074658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
    Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
    Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TYPE 3 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
    Kuehlewein L; Dansingani KK; de Carlo TE; Bonini Filho MA; Iafe NA; Lenis TL; Freund KB; Waheed NK; Duker JS; Sadda SR; Sarraf D
    Retina; 2015 Nov; 35(11):2229-35. PubMed ID: 26502007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion.
    Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S
    Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
    Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.
    Schütze C; Wedl M; Baumann B; Pircher M; Hitzenberger CK; Schmidt-Erfurth U
    Am J Ophthalmol; 2015 Jun; 159(6):1100-1114.e1. PubMed ID: 25769245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
    Inan S; Polat O; Karadas M; Inan UU
    Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
    [No Abstract]   [Full Text] [Related]  

  • 37. Significance of the hyperautofluorescent ring associated with choroidal neovascularisation in eyes undergoing anti-VEGF therapy for wet age-related macular degeneration.
    Camacho N; Barteselli G; Nezgoda JT; El-Emam S; Cheng L; Bartsch DU; Freeman WR
    Br J Ophthalmol; 2015 Sep; 99(9):1277-83. PubMed ID: 25777818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 100.